BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27532609)

  • 1. Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.
    Zhang L; Steele MB; Jenks N; Grell J; Suksanpaisan L; Naik S; Federspiel MJ; Lacy MQ; Russell SJ; Peng KW
    Hum Gene Ther Clin Dev; 2016 Sep; 27(3):111-22. PubMed ID: 27532609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
    Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
    Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
    Naik S; Nace R; Barber GN; Russell SJ
    Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.
    Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL
    Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
    LeBlanc AK; Naik S; Galyon GD; Jenks N; Steele M; Peng KW; Federspiel MJ; Donnell R; Russell SJ
    Hum Gene Ther Clin Dev; 2013 Dec; 24(4):174-81. PubMed ID: 24219832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer.
    Naik S; Galyon GD; Jenks NJ; Steele MB; Miller AC; Allstadt SD; Suksanpaisan L; Peng KW; Federspiel MJ; Russell SJ; LeBlanc AK
    Mol Cancer Ther; 2018 Jan; 17(1):316-326. PubMed ID: 29158470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
    Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
    Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV.
    Yarde DN; Naik S; Nace RA; Peng KW; Federspiel MJ; Russell SJ
    Cancer Gene Ther; 2013 Nov; 20(11):616-21. PubMed ID: 24176894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
    Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
    Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.
    Cook J; Peng KW; Witzig TE; Broski SM; Villasboas JC; Paludo J; Patnaik M; Rajkumar V; Dispenzieri A; Leung N; Buadi F; Bennani N; Ansell SM; Zhang L; Packiriswamy N; Balakrishnan B; Brunton B; Giers M; Ginos B; Dueck AC; Geyer S; Gertz MA; Warsame R; Go RS; Hayman SR; Dingli D; Kumar S; Bergsagel L; Munoz JL; Gonsalves W; Kourelis T; Muchtar E; Kapoor P; Kyle RA; Lin Y; Siddiqui M; Fonder A; Hobbs M; Hwa L; Naik S; Russell SJ; Lacy MQ
    Blood Adv; 2022 Jun; 6(11):3268-3279. PubMed ID: 35175355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene.
    Goel A; Carlson SK; Classic KL; Greiner S; Naik S; Power AT; Bell JC; Russell SJ
    Blood; 2007 Oct; 110(7):2342-50. PubMed ID: 17515401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
    Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
    Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses.
    Udayakumar TS; Betancourt DM; Ahmad A; Tao W; Totiger TM; Patel M; Marples B; Barber G; Pollack A
    Mol Cancer Res; 2020 Aug; 18(8):1232-1243. PubMed ID: 32366674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
    Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical efficacy of oncolytic VSV-IFNβ in treating cancer: A systematic review.
    Moglan AM; Albaradie OA; Alsayegh FF; Alharbi HM; Samman YM; Jalal MM; Saeedi NH; Mahmoud AB; Alkayyal AA
    Front Immunol; 2023; 14():1085940. PubMed ID: 37063914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates.
    Jenks N; Myers R; Greiner SM; Thompson J; Mader EK; Greenslade A; Griesmann GE; Federspiel MJ; Rakela J; Borad MJ; Vile RG; Barber GN; Meier TR; Blanco MC; Carlson SK; Russell SJ; Peng KW
    Hum Gene Ther; 2010 Apr; 21(4):451-62. PubMed ID: 19911974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curative one-shot systemic virotherapy in murine myeloma.
    Naik S; Nace R; Federspiel MJ; Barber GN; Peng KW; Russell SJ
    Leukemia; 2012 Aug; 26(8):1870-8. PubMed ID: 22425894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.
    Willmon CL; Saloura V; Fridlender ZG; Wongthida P; Diaz RM; Thompson J; Kottke T; Federspiel M; Barber G; Albelda SM; Vile RG
    Cancer Res; 2009 Oct; 69(19):7713-20. PubMed ID: 19773437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
    Saloura V; Wang LC; Fridlender ZG; Sun J; Cheng G; Kapoor V; Sterman DH; Harty RN; Okumura A; Barber GN; Vile RG; Federspiel MJ; Russell SJ; Litzky L; Albelda SM
    Hum Gene Ther; 2010 Jan; 21(1):51-64. PubMed ID: 19715403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy.
    Li H; Peng KW; Dingli D; Kratzke RA; Russell SJ
    Cancer Gene Ther; 2010 Aug; 17(8):550-8. PubMed ID: 20379224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.